## Michael Dunne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/787700/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Scientific Reports, 2021, 11, 11103.	1.6	7
2	The power of integrating imaging throughout the drug development process. Journal of Controlled Release, 2020, 317, 386-388.	4.8	0
3	Determining critical parameters that influence in vitro performance characteristics of a thermosensitive liposome formulation of vinorelbine. Journal of Controlled Release, 2020, 328, 551-561.	4.8	16
4	Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy. Advanced Drug Delivery Reviews, 2020, 163-164, 98-124.	6.6	77
5	Heat-activated drug delivery increases tumor accumulation of synergistic chemotherapies. Journal of Controlled Release, 2019, 308, 197-208.	4.8	42
6	Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer. Journal of Controlled Release, 2018, 282, 35-45.	4.8	33
7	Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics. ACS Nano, 2018, 12, 7583-7600.	7.3	55
8	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research, 2017, 187, 147-160.	0.7	44
9	The battle of "nano―paclitaxel. Advanced Drug Delivery Reviews, 2017, 122, 20-30.	6.6	270
10	Tumor microenvironment determines response to a heat-activated thermosensitive liposome formulation of cisplatin in cervical carcinoma. Journal of Controlled Release, 2017, 262, 182-191.	4.8	13
11	Thermosensitive nanomedicines could revolutionize thermal therapy in oncology. Nano Today, 2017, 16, 9-13.	6.2	20
12	Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma <sup>*</sup> . Journal of Drug Targeting, 2016, 24, 865-877.	2.1	18
13	Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model. Journal of Controlled Release, 2015, 207, 101-111.	4.8	84
14	Comparison of Computed Tomography– and Optical Image–Based Assessment of Liposome Distribution. Molecular Imaging, 2013, 12, 7290.2012.00028.	0.7	11
15	A Mathematical Model of the Enhanced Permeability and Retention Effect for Liposome Transport in Solid Tumors. PLoS ONE, 2013, 8, e81157.	1.1	66
16	A Novel Minimally Invasive Technique to Create a Rabbit VX2 Lung Tumor Model for Nano-Sized Image Contrast and Interventional Studies. PLoS ONE, 2013, 8, e67355.	1.1	37
17	Comparison of computed tomography- and optical image-based assessment of liposome distribution. Molecular Imaging, 2013, 12, 148-60.	0.7	4
18	APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. Journal of Controlled Release, 2011, 154, 298-305.	4.8	76

MICHAEL DUNNE

#	Article	IF	CITATIONS
19	Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 161-169.	1.7	152
20	Delivery of smaller gold nanoparticles by liposomal incorporation. , 2010, , .		1
21	SUâ€DDâ€A2â€04: Functional Relationships between Imaging and Biological Markers for the Purpose of Dose Painting Using the Example of FLTâ€PET and the Kiâ€67 Labeling Index. Medical Physics, 2010, 37, 3090-3090.	1.6	0
22	In Vivo Performance of a Liposomal Vascular Contrast Agent for CT and MR-Based Image Guidance Applications. Pharmaceutical Research, 2007, 24, 1193-1201.	1.7	103
23	TU-C-330A-09: Performance of CT and MR-Based Assays for In Vivo Agent Concentration Quantitation. Medical Physics, 2006, 33, 2184-2184.	1.6	0
24	Sci-Fri PM Imaging-12: Multimodal Contrast Agent for Combined CT and MR Imaging. Medical Physics, 2006, 33, 2672-2672.	1.6	0
25	Methoxy Poly(ethylene glycol)-block-Poly(δ-valerolactone) Copolymer Micelles for Formulation of Hydrophobic Drugs. Biomacromolecules, 2005, 6, 3119-3128.	2.6	98